Shi Siyao Group (02005) issued an announcement that the group has obtained relevant information from the State Food and Drug Administration of China on linezolid dry suspension (5ml)bonusgame: 100mg) of drug production registration approval document belongs to Class 4 of chemical drugs and is deemed to have passed the consistency evaluation.
The announcement stated that linezolid dry suspension is an oral suspension type. The group is the first domestic company to be approved and has previously obtained production approvals for linezolid's raw materials and injections. Linezolid dry suspension can be used in newborns, children and adult patients, mainly for the treatment of nosocomial pneumonia caused by sensitive strains of specific microorganisms, community-acquired pneumonia, skin and skin soft tissue infections, and vancomycin-resistant Enterococcus faecium infections.
